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Summary
In solid organ transplant recipients (sOTRs), 5 years after
transplantation cancer is a relevant cause of death. We
aimed to report cancer incidence in the Swiss Transplant
Cohort Study (STCS) between 2008 and 2014 and con-
ducted a prospective cohort study of kidney, heart, lung,
pancreas and liver transplant recipients enrolled into the
STCS by retrospective analysis of collected data. The
STCS provided data on 2758 solid organ transplants. In
total, 134 cases of cancer were observed (30 liver, 21
prostate, 18 lung, 13 kidney, 52 other cancers). Standard-
ised incidence ratios (SIRs) were highest for liver cancer,
kidney cancer, thyroid cancer, gastric cancer, bladder can-
cer, cancer of the oral cavity and the pharynx and for lung
cancer. Cancer occurrence differed according to the trans-
planted organ. Cancers were mainly diagnosed at World
Health Organisation (WHO) stages I and IV. Treatment re-
ceived was mainly surgery and, in some cases, included
also radiation and/or chemotherapy. Bladder, kidney, liv-
er, lung and prostate cancer were detected at a younger
age compared with the general population. Cumulative
hazards for death were increased for transplant recipients
with cancer. Solid organ transplant recipients show an or-
gan specific increase of cancer compared with the general
Swiss population.
Clinical trial registration number: NCT02333279
Keywords: solid organ transplantation, cancer, kidney
transplantation, heart transplantation, liver transplanta-
tion, lung transplantation, pancreas transplantation, non-
cutaneous malignancies, immunosuppression
Introduction
There is a large body of evidence indicating that 4 to 5%
of solid organ transplant recipients (sOTRs) develop a ma-
lignancy after transplantation [1], which corresponds to an
approximately two- to four-fold elevated risk compared to
the general population [2–5]. According to a US study,
the risk for malignancies is elevated for 32 different can-
cer types, with the highest risk for non-Hodgkin’s lym-
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phoma, lung cancer, liver cancer and kidney cancer [2].
The risk for infection-related malignancies (such as liver
cancer) is generally higher than for non-infection-related
malignancies; however, some non-infection-related malig-
nancies, such as lip cancer, kidney cancer, thyroid cancer
and others, are also more common in sOTRs than in the
general population [2] [6]. Squamous cancer of the lip,
non-Hodgkin’s lymphoma, kidney and bladder cancer are
the most reported cancer types in kidney transplant recipi-
ents [4] [7]. In heart transplant recipients, the risk is most
elevated for non-Hodgkin’s lymphoma, oral cancer (com-
prising cancers of the oral cavity, oropharynx and lips) and
lung cancer [8]. An Australian study associated lung trans-
plantation with an increased risk for non-Hodgkin’s lym-
phoma, Merkel cell carcinoma and cancers of the vulva,
lip, lung and colorectum. The same study showed an ele-
vated risk for non-Hodgkin’s lymphoma, Kaposi sarcoma,
colorectal cancer and lip cancer after liver transplantation
[4].
The STCS aims at a comprehensive and structured data
collection for all solid organ transplant recipients in
Switzerland since May 2008 [9]. Our objective is to report
the aggregated results of solid cancer cases occurring in
this Swiss Transplant cohort. With the hypothesis of in-
creased cancer incidence, we compare their incidence to
the general population and report on treatment and out-
come.
Methods
Swiss transplant registry and collection of data
The STCS collects data from all six transplantation centres
in Switzerland and started enrolment of patients in May
2008. Patients’ base-line data are collected at the time of
transplantation and the transplantation centres provide fol-
low-up data on recipients’ vital status, health issues and
graft function 6 and 12 months after transplantation, fol-
lowed by yearly follow-ups. There was no specific screen-
ing procedure beyond the public screening programmes.
Once a cancer became apparent in clinical follow-up, this
date was entered into the data base. Each cancer was
checked for histological findings to differentiate between
primary and metastatic cancers. A detailed description of
the design and methodology of the STCS is provided by
Koller et al. [10].
For our report, the following inclusion criteria were ap-
plied: all kidney, liver, heart, lung, pancreas, islet cell and
small bowel transplant recipients who were included in the
ABBREVIATIONS:
CI confidence interval
HBV hepatitis B virus
HCV hepatitis C virus
IQR interquartile range
NICER National Institute for Cancer Epidemiology and Registra-
tion
SEER Surveillance, Epidemiology and End Results Program
SIR standardised incidence ratio
sOTR solid organ transplant recipient
STCS Swiss Transplant Cohort Study
WHO World Health Organization
STCS data base between May 2008 and September 2014.
Patients with multiple organ transplantation were included
as well. Patients contributed to the study observation time
until death or end of follow-up for other reasons, up to the
censoring date of 31 December 2014. Patients with graft
loss remained in the study population and were assessed
in the subgroup of their original transplanted organ, since
they remained at risk for cancer development. Transplant
recipients with pre-existing malignancies were included to
adequately assess the overall cancer risk in our study pop-
ulation. In these patients, no pre-emptive modification in
immunosuppression regimens or post-transplant screening
strategies was pursued. There was no age restriction for
inclusion. Exclusion criteria were: withdrawal of consent,
a non-solid organ transplantation (such as haematopoietic
stem cell transplantation) as these transplant types are not
registered in the STCS, and if the information in the STCS
was insufficient for detailed analysis of cancer develop-
ment. Haematological malignancies (such as post-trans-
plant lymphoproliferative disorder) and skin cancers were
excluded from this analysis, as they will be addressed sep-
arately in another STCS report. All World Health Organi-
zation (WHO) stage 0 cases were excluded because of lim-
ited duration of follow up, limited biological relevance in
comparison with invasive cancers and inherent validation
uncertainty on data capture.
The two main points to avoid bias were: no selection of
specific sOTR, but all sOTRs in Switzerland included, thus
avoiding selection bias; the data collected in a prospective
manner and with uniform data collection protocols in all
centres in order to avoid bias of retrospective studies. The
cancer data for the reference group was provided by the
National Institute for Cancer Epidemiology and Registra-
tion (NICER). NICER compiles and aggregates data that
are collected by the different cantonal and regional cancer
registries of Switzerland and provided a corresponding ref-
erence group, since the NICER registry covers most of the
Swiss population [11].
Our study was approved by the respective local ethics
committee of all involved centres: ethics committee Bern,
ethics committee of northwest and central Switzerland,
ethics committee St Gallen, ethics committee Vaud, ethics
committee Geneva and the lead ethics committee Zurich
(Swiss national clinical trial portal number
SNCTP000000587).
Statistical analysis
For patients with multiple cancers, each cancer was treated
as a separate event for the statistical analysis. The expected
number of cancer cases in the SCTS was calculated as the
NICER Swiss cancer rate multiplied by observation time
in the STCS. Relative risks of cancer in transplant recipi-
ents compared to the general population were expressed as
standardised incidence ratios (SIRs) per 100,000 person-
years, i.e., observed/expected cases. The SIRs were calcu-
lated indirectly with the Swiss general population as refer-
ence population. Further, there was no stratification of our
population. Exact confidence intervals and p-values were
calculated based on the Byar formula [12] often applied in
similar studies [2].
We also calculated the median age at cancer diagnosis with
interquartile range (IQR), as well as the time from trans-
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plantation to first cancer occurrence with IQR. We applied
the Wilcoxon signed rank test to check for any difference
in median age at cancer detection in transplant recipients
compared with the general Swiss population with the re-
spective cancer type. The cumulative hazard function was
used to find any difference for the cumulative hazards for
death in transplant recipients with cancer compared with
those without cancer as described by Cleves et al. [13]. If
patients developed multiple cancers, the time of the first
cancer incidence was used to calculate the cumulative haz-
ards for death.
Results
The characteristics of our patient cohort are shown in table
1. Between May 2008 and September 2014, the STCS in-
cluded 2758 patients with a solid organ transplant, with a
median follow-up of 3 years, yielding 8563 person-years.
They received 1557 (56.5%) kidney transplants, 557
(20.2%) liver transplants, 278 (10.1%) lung transplants,
208 (7.5%) heart transplants and 158 (5.7%) other or com-
bined transplants (i.e., single pancreas, small bowel, islet
cells or combined, e.g. kidney-lung). The majority of trans-
plant recipients were male (63.9%). As shown in table 2,
the infection rates for hepatitis B virus (HBV) and hepatitis
C virus (HCV) were reported to be higher for liver trans-
plant recipients, as HBV and HCV often lead to liver cir-
rhosis and therefore to liver transplantation. The number
of malignancies before STCS inclusion was also higher in
patients with liver transplant, since previous liver cancer
made the patients eligible for a liver transplant. Most trans-
plant recipients were treated with an immunosuppressive
regimen comprising calcineurin inhibitors (95.5%) and
mycophenolate mofetil (90.7%).
All post-transplant cancer findings (141 patients) regis-
tered in the STCS data base were verified by reviewing the
patient files in the respective hospitals. Eighteen patients
were excluded. In 13 patients, each with one cancer, cancer
diagnosis could not be validated (e.g., a benign tumour was
registered as cancer or the cancer occurred before trans-
plantation). In another five patients, the transplant was be-
fore May 2008 and thus did not meet inclusion criteria.
No patient had to be excluded because of insufficient da-
ta. In the remaining 123 patients, a total of 134 malignan-
cies were noted (66 malignancies in kidney transplant re-
Table 1: Patient characteristics.
Transplanted or-
gan
Kidney Liver Lung Heart Other Total
Patients, n (%) 1557 (56.5) 557 (20.2) 278 (10.1) 208 (7.5) 158 (5.7) 2758 (100.0)
Male sex, n (%) 1010 (64.9%) 365 (65.5%) 138 (49.6%) 156 (75%) 94 (59.5%) 1763 (63.9%)
Age at transplantation (years), median (IQR) 53.9 (41.7–62.9) 54.4 (43.9–61.2) 54.2 (37.7–60.6) 51.7 (38–59.8) 46.1 (38.4–54.8) 53.5 (41.4–61.8)
Previous transplantations, n (%) 264 (17%) 25 (4.5%) 10 (3.6%) 1 (0.5%) 40 (25.3%) 340 (12.3%)
Re-/second transplantations, n (%) 29 (1.9%) 37 (6.6%) 8 (2.9%) 1 (0.5%) 19 (12%) 94 (3.4%)
– Re-transplantations, n 24 31 8 1 15 79
– Second transplantations (different organ), n 5 6 0 0 4 15
Cancer before transplantation, n (%) 165 (10.6%) 223 (40%) 26 (9.4%) 8 (3.8%) 13 (8.2%) 435 (15.8%)
Time of follow-up (years), median (IQR) 3.3 (1.6–5) 2.7 (1.2–4.5) 2.6 (1.1–3.8) 2.6 (0.9–4.3) 3 (1.4–4.8) 3 (1.4–4.8)
Primary non-function, n (%) 15 (1%) 11 (2%) 1 (0.4%) 3 (1.4%) 5 (3.2%) 35 (1.3%)
Graft loss, n (%) 96 (6.2%) 43 (7.7%) 31 (11.2%) 14 (6.7%) 34 (21.5%) 218 (7.9%)
Dropout, n (%) 11 (0.7%) 3 (0.5%) 1 (0.4%) 1 (0.5%) 4 (2.5%) 20 (0.7%)
Death, n (%) 104 (6.7%) 90 (16.2%) 75 (27%) 38 (18.3%) 15 (9.5%) 322 (11.7%)
IQR = interquartile range There were 8 patients with both primary non-function and graft loss for different organ transplants. The baseline for immunosuppressive medication was
defined as medication start within 7 days before and 7 days after transplantation. Other transplanted organs included multiple transplantations of different organs, single pancreas,
small bowel or islet cells transplantation.
Table 2: Serostatus and immunosuppressive medication at baseline.
Transplanted or-
gan
Kidney Liver Lung Heart Other Total
Serostatus at baseline
EBV positive, n (%) 1466 (94.2%) 475 (85.3%) 246 (88.5%) 188 (90.4%) 148 (93.7%) 2523 (91.5%)
– missing, n 7 26 2 1 3 39
CMV positive [n, (%)] 913 (58.6%) 384 (68.9%) 144 (51.8%) 110 (52.9%) 92 (58.2%) 1643 (59.6%)
– missing, n 6 0 0 0 4 10
HBV positive, n (%) 20 (1.3%) 55 (9.9%) 2 (0.7%) 3 (1.4%) 2 (1.3%) 82 (3%)
– missing, n 5 6 2 0 2 15
HCV positive, n (%) 49 (3.1%) 153 (27.5%) 5 (1.8%) 2 (1%) 9 (5.7%) 218 (7.9%)
– missing, n 6 4 2 0 2 14
Immunosuppressive medication at baseline
Calcineurin inhibitors, n (%) 1508 (96.9%) 511 (91.7%) 275 (98.9%) 184 (88.5%) 155 (98.1%) 2633 (95.5%)
Mycophenolate mofetil, n (%) 1520 (97.6%) 383 (68.8%) 268 (96.4%) 184 (88.5%) 146 (92.4%) 2501 (90.7%)
mTOR-inhibitors, n (%) 17 (1.1%) 17 (3.1%) 1 (0.4%) 16 (7.7%) 10 (6.3%) 61 (2.2%)
Azathioprine, n (%) 12 (0.8%) 4 (0.7%) 4 (1.4%) 45 (21.6%) 4 (2.5%) 69 (2.5%)
CMV = cytomegalovirus; EBV = Epstein-Barr virus; HBV = hepatitis B virus; HCV = hepatitis C virus; mTOR = mammalian target of rapamycin Other transplanted organs included
multiple transplantations of different organs, single pancreas, small bowel or islet cells transplantations.
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cipients, 53 in liver, 7 in lung, 6 in heart and 2 in combined
transplant patients) (table 3). High numbers were found for
liver cancer in liver transplant recipients (n = 29, a total of
30 liver cancers), of whom 27 patients had liver malignan-
cy before transplantation. In kidney transplant recipients,
high numbers of prostate (n = 18), kidney (n = 13), lung
(n = 8), bladder (n = 5) and thyroid cancers (n = 5) were
noted. In total, in 4.5% of all transplant recipients included
in our analysis cancer was observed, and the incidence was
especially high in liver transplant recipients (8.8%).
The cancer incidence within the STCS was compared with
the general Swiss population by calculation of the SIR. For
kidney transplant recipients, an elevated SIR was found
for kidney, thyroid, brain, bladder and prostate cancer. In
liver transplant recipients, higher incidences were reported
for liver, oral cavity and pharyngeal, pancreas, gastric and
lung cancer (table 4). In the remaining transplant recipi-
ents, a higher risk for lung cancer in lung transplant recip-
ients and for testicular cancer in heart transplant recipients
was detected.
In our analysis of the median age at cancer diagnosis, we
detected an earlier occurrence of bladder, kidney, liver,
lung and prostate cancer. For the other cancer types, no dif-
ference was detected (fig. 1).
As shown in table 5, most cancer cases were diagnosed at
either WHO stage IV (n = 56) or stage I (n = 40). More
specifically, of 30 liver cancers, 25 were WHO stage IV at
the time of diagnosis. Kidney cancers were more likely to
be diagnosed at earlier stages as 13 out of 14 kidney can-
cers were registered at WHO stage I.
Patients’ files were searched to capture all treatments pa-
tients received related to their cancers. The treatments are
reported in table 6, according to affected organ and histo-
logical subtype. Treatment was grouped for patients who
received surgery (total n = 73), chemotherapy (total n =
22), radiotherapy (total n = 24) and other therapies (total
n = 126), such as transurethral resection of the prostate or
hormonal therapy.
Figure 2 shows the cumulative hazards for death within
the STCS for transplant recipients with cancer compared
to those without cancer. The hazards for death in the pop-
ulation with cancer increase early after transplantation and
become less common after 2 years of follow-up, whereas
for the population without cancer the hazards for death in-
creases only slowly over time.
Discussion
In this first analysis of the Swiss Transplant Cohort Study,
we found 134 cancers, corresponding to 4.5% of all trans-
plant recipients, with a median follow-up time of 3 years.
An increased risk was seen for a wide range of malignan-
cies.
Our patients showed characteristics similar to populations
in similar studies. Other cohorts have included 175,732
[2], 193,905 [5] and 5931 [14] patients, whereas our study
oversees 2758 sOTRs. A higher proportion of male than
female sOTRs was reported by Engels et al. (60.9% male),
Sampaio et al. (53.9–80.6%, depending on transplant type)
and Adami et al. (61%) [2, 5, 14]. The median age at
transplantation for our population was higher than docu-
mented by Engels et al. (47 years) and Adami et al. (46
Table 3: Solid cancers by organ affected.
ICD-10 Transplanted
organ
Kidney Liver Lung Heart Other Total
Cancer by organ affected
Oral cavity and pharynx C00-14 1 4 0 0 0 5
Oesophagus C15 1 0 0 0 0 1
Stomach C16 2 2 1 0 0 5
Small intestine C17 1 0 0 0 0 1
Colon, rectum C18–20 1 2 1 0 0 4
Anus, anal canal C21 0 1 0 0 0 1
Liver C22 1 29 0 0 0 30
Extrahepatic bile duct C23–24 1 0 1 0 0 2
Pancreas C25 0 4 0 0 0 4
Vocal cord C32 0 1 0 0 0 1
Lung C33–34 8 5 4 1 0 18
Connective tissue C47, C49 1 0 0 0 0 1
Breast C50 3 0 0 0 0 3
Prostate C61 18 0 0 2 1 21
Testis C62 0 0 0 2 0 2
Kidney C64 13 0 0 0 0 13
Bladder C67 5 0 0 1 0 6
Brain C70–72 3 0 0 0 0 3
Thyroid C73 5 0 0 0 1 6
Endocrine system n.a. 1 2 0 0 0 3
Vascular system n.a. 1 2 0 0 0 3
Unknown primary n.a. 0 1 0 0 0 1
Total n of cancers (% of transplant recipients) 66 (3.8%) 53 (8.8%) 7 (2.5%) 6 (2.9%) 2 (1.3%) 134 (4.5%)
Time to cancer (months), median (IQR) 24.5 (13.1–41.5) 18 (6.3–28.4) 22.3 (12.7–49.9) 25.3 (22.2–39.2) 5.3 (3.3–7.3) 21.1 (9.8–34.5)
ICD-10 = International statistical classification of diseases and related health problems (Version 10, 2016); IQR = interquartile range. Other transplanted organs included multiple
transplantations of different organs, single pancreas, small bowel or islet cells transplantations.
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years) [2, 14]. Our population included a small propor-
tion of patients with re-transplants, who have less exposure
to immunosuppression than patients with previous trans-
plants. Our follow-up time was relatively short compared
Table 4: Cancer risk by transplanted organ type.
Cancer by organ
system affected
Transplanted
organ
Kidney Liver Lung Heart Other Total
SIR 95% CI SIR 95% CI SIR 95% CI SIR 95% CI SIR 95% CI SIR 95% CI
Oral cavity and
pharynx
1.38 0.02–7.69 17.72 4.77–45.36 – – – 4.17 1.34–9.73
Oesophagus 2.76 0.04–15.38 – – – – 1.67 0.02–9.28
Stomach 3.52 0.4–12.7 11.28 1.27–40.71 12.47 0.16–69.37 – – 5.31 1.71–12.39
Small intestine 8.06 0.11–44.86 – – – – 4.87 0.06–27.07
Colon, rectum 0.37 0–2.04 2.34 0.26–8.47 2.59 0.03–14.43 – – 0.88 0.24–2.26
Anus, anal canal 24.81 0.32–139.02 24.81 0.32–138.02 – – – 4.67 0.06–25.99
Liver 1.95 0.03–10.87 181.67 121.64–260.91 – – – 35.39 23.87–50.52
Extrahepatic bile
duct
4.96 0.06–27.6 – 35.17 0.46–195.67 – – 5.99 0.67–21.62
Pancreas – 15.70 4.22–40.2 – – – 2.96 0.8–7.57
Vocal cord – 18.24 0.24–101.48 – – – 3.43 0.04–19.11
Lung 2.99 1.29–5.9 6.00 1.93–14 10.61 2.85–27.17 3.50 0.05–19.48 – 4.07 2.41–6.43
Connective tissue 5.69 0.07–31.66 – – – – 3.43 0.04–19.11
Breast 0.78 0.16–2.27 – – – – 0.47 0.09–1.37
Prostate 4.47 2.64–7.06 – – 4.64 0.52–16.76 2.56 0.03–14.24 3.14 1.95–4.81
Testis – – – 90.57 10.17–327 – 6.77 0.76–24.43
Kidney 22.26 11.84–38.07 – – – – 13.43 7.15–22.98
Bladder 6.67 2.15–15.57 – – 12.49 0.16–69.47 – 4.83 1.76–10.52
Brain 7.44 1.5–21.74 – – – – 4.49 0.9–13.12
Thyroid 10.75 3.46–25.09 – – – 22.18 0.29–123.42 7.79 2.84–16.95
Endocrine system n.a. n.a. n.a. n.a. n.a. n.a.
Vascular system n.a. n.a. n.a. n.a. n.a. n.a.
Unknown primary n.a. n.a. n.a. n.a. n.a. n.a.
CI = confidence interval; n.a. = not applicable; SIR = standardised incidence ratio Other transplanted organs included multiple transplantations of different organs, single pancreas,
small bowel or islet cells transplantations. "-" means that there were no cancer cases. Significantly different SIR are printed in bold type. "n.a." means that there was no data for
the general population available and thus no SIR could be calculated..
Figure 1: Comparison of age at cancer diagnosis. Black bars represent the Swiss population. White bars represent the Swiss transplant co-
hort study population. Differences in age were calculated using the Wilcoxon test, with respective p-values shown for each cancer. Right col-
umn shows number of patients. The single dot at lung cancer represents a statistical outlier. No. = numbers; STCS = Swiss Transplant Cohort
Study
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with Adami et al. (6.8 years) and Engels et al., who in-
cluded patients from as early as 1987 [2] [14]. The pro-
portion of graft failures within our follow-up was small-
Figure 2: Cumulative hazards for death within the Swiss Trans-
plant Cohort Study (STCS) cohort. Cumulative hazard function af-
ter time of transplantation expressed as the number of events to
be expected for any solid organ transplant recipients at the corre-
sponding time of follow-up.
er than that reported by Kim et al. (approximately 20%
for liver transplants) and Hart et al. (approximately 8%
for kidney transplants) [15, 16]. In comparison with oth-
er cohorts, our study group seems similar in composition,
although smaller. The serostatus for HBV and HCV was
more commonly positive in liver transplant recipients than
non-liver transplant recipients and was comparable to the
findings of Hoffmann et al. (5.7% HBV positive in liver
transplant recipients versus 1.4% in non-liver transplant re-
cipients; 36.8% HCV positive versus 3.9%, respectively)
[17].
We observed incidence rates of malignancies in our cohort
higher than in the general population for eight cancer
types, namely cancer of the liver, kidney, thyroid, stomach,
bladder, oral cavity and pharynx, lung and prostate. Our
findings are for the most part consistent with Engels et al.
who also found an increased risk for the cancer types men-
tioned previously (liver: SIR 11.56, 95% CI 10.83–12.33;
kidney: SIR 4.65, 95% CI 4.32–4.99; thyroid: SIR 2.95,
95% CI 2.58–3.34; stomach: SIR 1.67, 95% CI 1.42–1.96;
Table 5: Cancer WHO stage at detection.
Cancer by organ system affected Histological type n WHO stage
I II III IV n.a.
Oral cavity and pharynx Squamous cell carcinoma 5 2 0 2 1 0
Oesophagus Squamous cell carcinoma 1 0 0 1 0 0
Stomach Adenocarcinoma 4 0 1 0 3 0
Signet-ring cell carcinoma 1 1 0 0 0 0
Small intestine Neuroendocrine carcinoma 1 0 1 0 0 0
Colon, rectum Adenocarcinoma 2 0 0 2 0 0
Sarcoma 1 1 0 0 0 0
Unknown 1 0 0 0 0 1
Anus, anal canal Squamous cell carcinoma 1 0 0 1 0 0
Liver Cholangiocarcinoma 5 0 0 0 5 0
Hepatocellular carcinoma 25 0 4 1 20 0
Extrahepatic bile duct Cholangiocarcinoma 2 0 2 0 0 0
Pancreas Adenocarcinoma 1 0 0 0 1 0
Neuroendocrine carcinoma 2 0 0 0 2 0
Pancreatoblastoma 1 0 0 0 1 0
Vocal cord Squamous cell carcinoma 1 1 0 0 0 0
Lung Small cell carcinoma 5 0 0 1 4 0
Adenocarcinoma 12 2 3 3 4 0
Squamous cell carcinoma 1 0 0 0 1 0
Connective tissue Chondrosarcoma 1 1 0 0 0 0
Breast Invasive ductal carcinoma 2 0 1 0 1 0
Tubular carcinoma 1 1 0 0 0 0
Prostate Adenocarcinoma 21 7 8 3 3 0
Testis Mixed germ cell tumour 1 1 0 0 0 0
Seminoma 1 1 0 0 0 0
Kidney Clear cell renal cell carcinoma 4 4 0 0 0 0
Mucinous tubular spindle cell carcinoma 1 1 0 0 0 0
Papillary renal cell carcinoma 8 7 0 1 0 0
Bladder Urothelial carcinoma 6 4 1 0 1 0
Brain Astrocytoma 1 1 0 0 0 0
Glioblastoma 1 0 0 0 1 0
Meningioma 1 0 1 0 0 0
Thymus Papillary adenocarcinoma 6 4 0 0 2 0
Endocrine system Neuroendocrine carcinoma 3 1 0 0 2 0
Vascular system Angiosarcoma 1 0 0 0 1 0
Kaposi sarcoma 2 0 0 0 2 0
Unknown primary Unknown 1 0 0 0 1 0
Total 134 40 22 15 56 1
n.a. = not applicable. Tumors in WHO stage 0 were not included for analysis, see methods.
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bladder: SIR 1.52, 95% CI 1.33–1.73; oral cavity and phar-
ynx: SIR 2.56, 95% CI 2.17–3.01; lung: SIR 1.97, 95% CI
1.86–2.08), whereas the risk for prostate cancer was not in-
creased. Engels et al. were, however, able to report a high-
er risk for multiple other cancer types thanks to a larger
study population, potentially also due to other factors, such
as medication or difference in genetic background [2].
Hoshida et al. showed an increased relative risk for malig-
nancies in the kidney (SIR 79.96, 95% CI 39.98–114.95)
and the thyroid (SIR 12.43, 95% CI2.38–33.70) in kidney
transplant recipients, which is in line with our findings.
They, however, did not find a higher risk for bladder,
prostate and brain cancer as our study did [18]. In larger
studies, Cheung et al. and Li et al. reported a greatly in-
creased risk for kidney cancers (SIR 12.5, 95% CI
8.51-18.36 and SIR 44.29, 95% CI 36.24–54.06) and blad-
der cancers (SIR 8.22, 95% CI 4.67–14.47 and SIR 42.89,
95% CI 34.08–53.98) in kidney transplant recipients, both
being attributed to multiple factors including immunosup-
pressive status, underlying renal diseases, genetic back-
ground and environmental factors [7, 19]. An often cited
reason for the elevated risk of kidney cancer in kidney
transplant recipients is the malignant transformation of
cysts that develop in end-stage renal disease [2, 7]. Lung
cancer risk was increased in lung transplant recipients.
This can probably be attributed to smoking-related lung
diseases, such as chronic obstructive pulmonary disease, as
indication for the lung transplant. Minal et al. and Dickson
et al. reported an increased risk for lung cancer, mostly in
single-lung recipients who develop lung cancer in the re-
maining native lung [20, 21]. Increased liver cancer risk
in liver transplant recipients is probably mainly due to two
factors. Firstly, liver transplantion is a common treatment
for hepatocellular cancer, with the risk for residual cancer
after the initial treatment. Thus, the post-transplant liver
cancers are not de novo but rather relapses of pre-existing
cancers. The second reason might be the high prevalence
of carcinogenic infections such as HBV or HCV. Frequent-
ly these infections drove the initial liver cancer that needed
liver transplantation in first place [2].
Table 6: Cancer treatment following diagnosis.
Cancer by organ af-
fected
Histological type n Surgery Chemotherapy Radiotherapy Other therapy
Oral cavity and pharynx Squamous cell carcinoma 5 5 1 1 1
Oesophagus Squamous cell carcinoma 1 1 0 0 0
Stomach Adenocarcinoma 4 0 2 0 0
Signet-ring cell carcinoma 1 1 0 0 0
Small intestine Neuroendocrine carcinoma 1 1 0 0 0
Colon, rectum Adenocarcinoma 2 2 2 1 0
Sarcoma 1 1 0 0 0
Unknown 1 0 0 0 0
Anus, anal canal Squamous cell carcinoma 1 0 0 0 0
Liver Cholangiocarcinoma 5 0 3 1 0
Hepatocellular carcinoma 25 7 4 4 6
Extrahepatic bile duct Cholangiocarcinoma 2 2 0 0 0
Pancreas Adenocarcinoma 1 0 0 0 0
Neuroendocrine carcinoma 2 1 0 0 1
Pancreatoblastoma 1 0 1 0 0
Vocal cord Squamous cell carcinoma 1 1 0 0 0
Lung Small cell carcinoma 5 0 3 1 0
Adenocarcinoma 12 8 3 4 0
Squamous cell carcinoma 1 0 1 0 0
Connective tissue Chondrosarcoma 1 1 0 1 0
Breast Invasive ductal carcinoma 2 1 0 0 2
Tubular carcinoma 1 1 0 0 0
Prostate Adenocarcinoma 21 8 1 9 5
Testis Mixed germ cell tumor 1 1 0 0 0
Seminoma 1 1 0 0 0
Kidney Clear cell renal cell carcinoma 4 4 0 0 0
Mucinous tubular spindle cell carcino-
ma
1 1 0 0 0
Papillary renal cell carcinoma 8 8 0 0 0
Bladder Urothelial carcinoma 6 5 1 0 0
Brain Astrocytoma 1 0 0 0 0
Glioblastoma 1 1 0 1 0
Meningioma 1 1 0 0 0
Thymus Papillary adenocarcinoma 6 6 0 1 2
Endocrine system Neuroendocrine carcinoma 3 3 0 0 0
Vascular system Angiosarcoma 1 0 0 0 0
Kaposi sarcoma 2 1 0 0 0
Unknown primary Unknown 1 0 0 0 0
Total 134 73 22 24 18
For therapies multiple options were possible. Some cancers were treated with multiple modalities.
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In general, the most cited reason for the increased cancer
risk in sOTRs is prolonged immunosuppressive therapy.
Long-term immunosuppression increases the risk of on-
covirally driven malignancies substantially [7]. A second
important mechanism is the nonspecific mode of action of
most immunosuppressive agents leading to impaired tu-
mour immunosurveillance. Third, some immunosuppres-
sive drugs have pro-oncogenic properties themselves in ad-
dition to their immunosuppressive properties. It has been
shown that calcineurin inhibitors such as ciclosporin, and
to a lesser extent azathioprine and prednisolone, cause a
significant impairment of DNA repair mechanisms or drive
cancer formation directly, leading to elevated cancer risk
in sOTRs [2] [22] [23]. Additionally, ciclosporin is linked
to promoting angiogenesis and invasiveness of non-trans-
formed cells in vitro by inducing transcription and expres-
sion of the TGF-β1 gene [7] [8].
Hoshida et al. described earlier cancer development in their
kidney transplant recipients. The median age of all their
cancer patients was 40.0 years, whereas for renal and blad-
der cancer it was 41.0 years and 43.5 years, respectively.
This corresponds to a clearly younger age at cancer devel-
opment compared with the general population in Japan (64
years) [18]. This study analysed only kidney transplant re-
cipients, but their findings conform to our results on the
subgroup of kidney transplant recipients in the STCS.
Cancer stages at diagnosis for lung cancer were compara-
ble to the data for the general Swiss population. According
to the Surveillance, Epidemiology, and End Results Pro-
gram (SEER) database, lung cancers are most often de-
tected in WHO stage IV (57%) and less often in region-
al (22%) or localised (16%) stages [24]. Liver cancers are
commonly found in a localised stage (44%) and less fre-
quently in regional (27%) or metastasised (18%) stages
[25]. Our high proportion of WHO stage IV at diagno-
sis for liver cancer is probably caused by the high preva-
lence of liver cancer in liver transplant recipients before
transplantation. Kidney cancers are mostly diagnosed at
localised stages (65%) and less so at regional (16%) or
metastasised stages (16%), whereas in our population the
cancers were almost exclusively found in WHO stage I,
potentially related to closer follow-up in kidney transplant
recipients [26]. For prostate cancer, our findings are com-
parable to the findings of Rohrmann et al., who report-
ed cancer detection mostly in stage I (38.4%) and stage
II (22.7%) and less often in stage III (13.1%) and stage
IV (10.8%) [27]. In summary, cancer stage at diagnosis
for prostate and lung cancer were comparable to the gen-
eral Swiss population, whereas liver and kidney cancers
showed a different pattern.
We found that kidney cancers in the STCS cohort received
surgical treatment only, potentially because of rather limit-
ed disease. For other common cancer types, such as liver,
lung and prostate cancer, the treatment often included se-
rial and multi-modal therapies, as would be expected for
these kinds of cancer. Zhou et al. described a 5-year overall
mortality of 30.4% for liver recipients with de novo malig-
nancies after transplantation and 31.4% mortality for liver
recipients without malignancy [28]. The higher mortality
for sOTRs without cancer does not support our findings of
an increased cumulative hazard of death for sOTRs with
cancer. We observed a higher incidence of all-cause death
for sOTRs with cancer in the first 2 years compared with
later years after transplantation. We speculate that by the
onset of immunosuppression at transplantation, the natur-
al course of disease for cancer would be accelerated. Thus,
patients with incipient and as yet undiagnosed cancer at
transplantation would fare worse under immunosuppres-
sion, contributing to all-cause death in the first 2 years
more than in later years.
Although our study gives an overview of the cancer risk
in sOTRs, it is limited by the relatively small population
size and therefore small number of incident cancers, which
does not yet allow any detailed analysis owing to the limit-
ed follow-up time, as cancer incidence probably increases
with prolonged immunosuppressive treatment. As the
STCS as a prospective cohort will continue to collect data,
later studies will provide longer-term data. Also, some pa-
tients had prior transplantations in some of which different
organs were transplanted. These patients had been exposed
to potentially cancer-inducing risk (immunosuppression)
prior to inclusion in our study. Because there were only a
few patients with prior transplantations, we did not calcu-
late the SIRs for them separately. Additionally, there was
no uniform protocol for cancer screening prior to trans-
plantation across all centres, which may have led to an
overestimation of cancer incidence. Further limitations in-
clude potential divergences between cancer at diagnosis
and staging, as full staging was only performed several
weeks or months after cancer diagnosis, which may cause
an overestimation of initial cancer stages. For the evalua-
tion of cancer treatment, we searched patient files outside
of the structured cohort data that are prospectively gath-
ered. Therapies may not all have been registered for patient
charts outside the cohort; this may have caused an under-
estimation of cancer treatments.
The strengths of our study include the inclusion of all
sOTRs in Switzerland during the study period, as every
transplantation centre in Switzerland has to provide min-
imum data to the STCS. Even patients moving within
Switzerland were usually not lost to follow-up as they con-
tinued to be monitored by a different transplantation centre
that is an active member of the STCS. Also, the relatively
limited number of cancers allowed us to double-check all
the findings by source verification in patient files. There-
fore, incorrectly entered malignancies could be eliminated
for our analysis.
In conclusion, we were able to give an overview of the
cancer risk in Swiss sOTRs, who are susceptible to a wide
range of cancer types. Depending on the transplant, sOTRs
were at increased risk for different cancers. Kidney trans-
plant recipients were at an increased risk for renal cell car-
cinoma, and prostate, bladder, thyroid and brain cancer;
liver transplant recipients were more likely to develop he-
patocellular carcinomas, gastric, pancreas and lung can-
cers, and cancer of the oral cavity and pharynx. For lung
transplant recipients we observed an increased risk of lung
cancer, whereas in heart transplant recipients risk was in-
creased for cancer of the testis. Building on the results of
our study, with a short follow-up but a reliable cohort, ex-
tended studies will help to improve cancer surveillance and
prevention strategies in sOTRs.
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